Skip header and navigation

3 records – page 1 of 1.

5-Aminosalicylate (5-ASA)

http://libcat.nshealth.ca/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Colitis - drug therapy
Crohn Disease - drug therapy
Inflammatory Bowel Diseases - drug therapy
Other Subjects
Colitis
Crohn's disease
Inflammatory bowel diseases
Abstract
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Responsibility
Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Alison Harding, B.Sc.
Revised by: Phyllis Durning, RN
Pamphlet Number
1483

Ustekinumab (Stelara®) therapy for Crohn's disease

http://libcat.nshealth.ca/permalink/chpams35722
Nova Scotia Health Authority. QEII. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1695
Available Online
View Pamphlet
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing thi…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Gastroenterology
Editor
Leddin, Desmond, J. (MD, Gastroenterology)
Stewart, Jennifer (RN, CCRP)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Crohn Disease - drug therapy
Ustekinumab
Other Subjects
Crohn's disease
Gastrointestinal agents
Abstract
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Alison Harding, BSc; Gastroenterology
Pamphlet Number
1695

Vedolizumab (Entyvio®) therapy

http://libcat.nshealth.ca/permalink/chpams35620
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Gastrointestinal Agents
Other Subjects
Crohn's disease
Gastrointestinal agents
Ulcerative colitis
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Allison Harding BSc & Jennifer Stewart RN, CCRP; Division of Gastroenterology
Pamphlet Number
1623

Revise Search

Narrow By

   MORE